SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 12/3/2016 1:37:47 AM - Followers: 834 - Board type: Free - Posts Today: 4

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Amended Annual Report (10-k/a) 11/17/2016 04:05:38 PM
ELTP News: Amended Quarterly Report (10-q/a) 11/17/2016 04:03:30 PM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 11/09/2016 05:10:17 PM
ELTP News: Quarterly Report (10-q) 11/09/2016 04:42:48 PM
ELTP News: Current Report Filing (8-k) 09/01/2016 04:32:35 PM
PostSubject
#234974  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE namtae 12/01/16 09:52:20 AM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#233080  Sticky Note Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 Couch 11/11/16 04:34:51 AM
#230575  Sticky Note I agree: ELTP is way Undervalued!!! SequestOx will Bngo 10/18/16 12:28:51 PM
#222196  Sticky Note Freedom of Information Act Request to FDA WeeZuhl 08/17/16 07:21:46 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#235111   Most people can't comprehend 1 Billion the amount stockboy 12/03/16 01:37:46 AM
#235110   Sorry you can't be helped Goodtimes93 12/03/16 12:32:53 AM
#235109   Why are you clueless? aELmTPa 12/03/16 12:10:45 AM
#235108   You are clueless Goodtimes93 12/03/16 12:00:16 AM
#235107   I agree with you that we will be aELmTPa 12/02/16 11:49:05 PM
#235106   More comedy. Goodtimes93 12/02/16 11:27:06 PM
#235105   Maybe .20s.... can't see it going to .40s doncamel 12/02/16 11:00:21 PM
#235104   100 million plus ANDA next week plus FDA aELmTPa 12/02/16 10:56:59 PM
#235103   Completely. Pps is going down and Goodtimes93 12/02/16 09:54:40 PM
#235101   Will be there soon. Don't worry. Goodtimes93 12/02/16 09:41:43 PM
#235100   It's was $0.11 in July. Stuck at $0.14 NASDAQ2020 12/02/16 09:32:34 PM
#235099   Won't be long. Gets closer by Goodtimes93 12/02/16 08:35:31 PM
#235098   Celebrating when you bank account shrinks? We can Couch 12/02/16 08:21:21 PM
#235097   Celebrating when you bank account shrinks? Goodtimes93 12/02/16 06:55:05 PM
#235096   If ELTP closes under 14 today, I fear Couch 12/02/16 05:39:57 PM
#235095   i know, thats why i suggested it. lol steve9465 12/02/16 05:37:36 PM
#235093   No it Doesn't ~~~Investors are treading water until toybaby 12/02/16 04:54:22 PM
#235092   No go read the 10Q the numbers went stockboy 12/02/16 04:37:21 PM
#235091   Gobbably gook based on Fantasy~ toybaby 12/02/16 04:35:39 PM
#235090   You may be right. It is Goodtimes93 12/02/16 04:33:47 PM
#235089   Because the numbers are based on BS stockboy 12/02/16 04:31:47 PM
#235088   Just how do you know THAT~~~~~ toybaby 12/02/16 04:24:46 PM
#235086   Right now NasRAT is all talk and has stockboy 12/02/16 04:18:24 PM
#235085   Next years revenues $12-20 million for generics. NASDAQ2020 12/02/16 04:16:56 PM
#235084   Don't worry it's only going lower. Did you stockboy 12/02/16 04:14:43 PM
#235083   Continuous sell side pressure like this will drive Goodtimes93 12/02/16 04:13:46 PM
#235081   With NONE on the market what revenue are stockboy 12/02/16 04:12:05 PM
#235078   The writing is on the wall the stock stockboy 12/02/16 04:07:34 PM
#235077   Yeah they could have 200 and it's not stockboy 12/02/16 04:06:22 PM
#235075   What in the hell are they good for tenor15824 12/02/16 03:59:20 PM
#235074   Total BS - 06 isn't coming soon - Couch 12/02/16 03:57:04 PM
#235073   We are already worth more than Epic was NASDAQ2020 12/02/16 03:42:08 PM
#235072   Elite has over 20 FDA approved generics, NASDAQ2020 12/02/16 03:40:29 PM
#235071   Sorry Stuckboy.... not a flipper.. no worries here. Gman24 12/02/16 03:37:12 PM
#235070   Anyone hear execs have been flying to Costa namtae 12/02/16 03:36:04 PM
#235069   $.06 coming soon. 90% sell today is Goodtimes93 12/02/16 03:34:16 PM
#235068   Hang in there Snup. Think of that old tenor15824 12/02/16 03:34:12 PM
#235067   If ELTP closes under 14 today, I fear namtae 12/02/16 03:27:54 PM
#235066   We had news coming to on July 14th, stockboy 12/02/16 03:26:22 PM
#235065   If they can stay in business another 4 stockboy 12/02/16 03:24:43 PM
#235064   Wow lots of selling today right before the stockboy 12/02/16 03:17:16 PM
#235063   New PPS contest January 1st 2017. stockboy 12/02/16 03:14:35 PM
#235062   Every time this falls lower it's some lame stockboy 12/02/16 03:12:26 PM
#235061   Epic? Purepak? Humanwell where are you? snupoled 12/02/16 02:41:25 PM
#235060   I never use AON. John_Langston 12/02/16 01:51:04 PM
#235059   Then put your bid in@ .01 for 2 steve9465 12/02/16 01:43:18 PM
#235058   Although I disagree with your position on the doncamel 12/02/16 01:42:42 PM
#235056   Heres why namtae 12/02/16 01:36:45 PM
#235054   Indeed, Let the weak hands go. I like Gman24 12/02/16 01:22:40 PM
#235053   Just lowered my bid to sub .05, should namtae 12/02/16 01:22:22 PM
PostSubject